Susan Kelley
Director/Miembro de la Junta en IDEAYA BIOSCIENCES, INC. .
Fortuna: - $ al 30/04/2024
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Daniel Flynn | M | 70 |
Deciphera Pharmaceuticals LLC
Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | 21 años |
Steven Hoerter | M | 53 |
Deciphera Pharmaceuticals LLC
Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | 6 años |
Andres Briseno | M | 38 | 8 años | |
Sabrina Johnson | F | 57 | 9 años | |
Rita Karachun | F | 63 | 5 años | |
James Bristol | M | 77 |
Deciphera Pharmaceuticals LLC
Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | 17 años |
Yujiro Hata | M | 49 | 9 años | |
Alexander Kamb | M | - |
A2 Biotherapeutics, Inc.
A2 Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services A2 Biotherapeutics, Inc. operates as a biotechnology company. It develops medicines. The company was founded by Alexander Kamb, Michael Gallo and Paul Kang in 2018 and is headquartered in Westlake Village, CA. | 6 años |
Ron Squarer | M | 57 |
Deciphera Pharmaceuticals LLC
Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | 5 años |
John Martin | M | 63 |
Deciphera Pharmaceuticals LLC
Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | 9 años |
Dennis Walsh | M | 56 |
Deciphera Pharmaceuticals LLC
Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | 9 años |
Patricia Allen | F | 62 |
Deciphera Pharmaceuticals LLC
Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | 8 años |
Franklin Friedman | M | 66 |
Deciphera Pharmaceuticals LLC
Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | 5 años |
Terry Rosen | M | 65 | 8 años | |
William Rastetter | M | 76 | 10 años | |
Caroline Litchfield | F | 55 | 5 años | |
Sophia Ononye-Onyia | M | 40 | 3 años | |
Paul A. Barsanti | M | - | 5 años | |
Michael L. Gallo | M | - |
A2 Biotherapeutics, Inc.
A2 Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services A2 Biotherapeutics, Inc. operates as a biotechnology company. It develops medicines. The company was founded by Alexander Kamb, Michael Gallo and Paul Kang in 2018 and is headquartered in Westlake Village, CA. | - |
Rajesh Devraj | M | - | 13 años | |
Robin Steele | F | 68 | 9 años | |
Garret Hampton | M | 58 | 4 años | |
Gregory Matz | M | 64 | 6 años | |
MarDee Haring-Layton | F | 47 | 6 años | |
Jama Pitman | M | 45 | 9 años | |
Jon Filderman | M | - | 5 años | |
Jason Throne | M | 53 | 5 años | |
Tucker Kelly | M | 53 | 9 años | |
Jeffrey Stein | M | 69 | 9 años | |
Catherine Mackey | M | 68 | 2 años | |
Edward Benz | M | 78 | 5 años | |
Jessica Grossman | M | 52 | 6 años | |
Wendy Yarno | F | 69 | 5 años | |
David Goeddel | M | 72 |
A2 Biotherapeutics, Inc.
A2 Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services A2 Biotherapeutics, Inc. operates as a biotechnology company. It develops medicines. The company was founded by Alexander Kamb, Michael Gallo and Paul Kang in 2018 and is headquartered in Westlake Village, CA. | - |
Cheryl Blanchard | M | 59 | 5 años | |
Scott Morrison | M | 66 | 6 años | |
Christine Mauck | M | - | 8 años | |
Mick O'Quigley | M | - | 6 años | |
Srini Akkaraju Akkaraju | M | 56 |
A2 Biotherapeutics, Inc.
A2 Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services A2 Biotherapeutics, Inc. operates as a biotechnology company. It develops medicines. The company was founded by Alexander Kamb, Michael Gallo and Paul Kang in 2018 and is headquartered in Westlake Village, CA. | - |
Michael White | M | - | 3 años | |
Rodrigo Ruiz Soto | M | - | 7 años | |
Kelley Dealhoy | F | - | 2 años | |
Kevin Brodbeck | M | - | 1 años | |
Jessica Hatheway | F | - | 2 años | |
Lisa Amaya Price | F | - | 2 años | |
Madhavan Balachandran | M | 73 |
A2 Biotherapeutics, Inc.
A2 Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services A2 Biotherapeutics, Inc. operates as a biotechnology company. It develops medicines. The company was founded by Alexander Kamb, Michael Gallo and Paul Kang in 2018 and is headquartered in Westlake Village, CA. | - |
Dashyant Dhanak | M | 63 | 1 años | |
David Chang | M | - |
A2 Biotherapeutics, Inc.
A2 Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services A2 Biotherapeutics, Inc. operates as a biotechnology company. It develops medicines. The company was founded by Alexander Kamb, Michael Gallo and Paul Kang in 2018 and is headquartered in Westlake Village, CA. | - |
Adriana Tajonar | M | - |
A2 Biotherapeutics, Inc.
A2 Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services A2 Biotherapeutics, Inc. operates as a biotechnology company. It develops medicines. The company was founded by Alexander Kamb, Michael Gallo and Paul Kang in 2018 and is headquartered in Westlake Village, CA. | - |
Jakob Loven | M | 46 |
A2 Biotherapeutics, Inc.
A2 Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services A2 Biotherapeutics, Inc. operates as a biotechnology company. It develops medicines. The company was founded by Alexander Kamb, Michael Gallo and Paul Kang in 2018 and is headquartered in Westlake Village, CA. | - |
David Friend | M | - | 6 años | |
David Chang | M | 64 |
A2 Biotherapeutics, Inc.
A2 Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services A2 Biotherapeutics, Inc. operates as a biotechnology company. It develops medicines. The company was founded by Alexander Kamb, Michael Gallo and Paul Kang in 2018 and is headquartered in Westlake Village, CA. | - |
Darrin Beaupre | M | - | 2 años | |
Daniel Martin | M | 49 | 6 años | |
Jeff Held | M | 55 | 6 años | |
Mark Walters | M | 69 | 9 años | |
Matthew Sherman | M | 68 | 5 años | |
Helen Kim | F | 61 |
A2 Biotherapeutics, Inc.
A2 Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services A2 Biotherapeutics, Inc. operates as a biotechnology company. It develops medicines. The company was founded by Alexander Kamb, Michael Gallo and Paul Kang in 2018 and is headquartered in Westlake Village, CA. | 5 años |
Annie Thurman | M | - | 2 años |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Paul Stone | M | 60 | 5 años | |
Walter Capone | M | 59 |
The Multiple Myeloma Research Foundation, Inc.
The Multiple Myeloma Research Foundation, Inc. Miscellaneous Commercial ServicesCommercial Services The Multiple Myeloma Research Foundation, Inc. provides funding for research on myeloma treatment. It provides funding to laboratories worldwide, including compounds and approaches in clinical trials and pre-clinical studies. The firm also facilitates clinical trials through their affiliate organization, the Multiple Myeloma Research Consortium. The company was founded by Karen E. Andrews and Kathryn E. Giusti in 1998 and is headquartered in Norwalk, CT. | - |
Oliver Fetzer | M | 60 |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | 5 años |
Nathan Drona | M | - | 3 años | |
Carlos Paya | M | 65 | 8 años | |
Roger L. Hawley | M | 71 | 4 años | |
Werner Baumann | M | 60 |
Bayer Pharma AG
Bayer Pharma AG Pharmaceuticals: MajorHealth Technology Bayer Pharma AG engages in the development and production of prescription drugs for the treatment of cardiovascular diseases and women's illnesses, as well as special therapy in the areas of oncology, hematology, and ophthalmology. It also offers medical equipment used in diagnostic imaging with applications in the field of radiology. The company was founded on March 9, 1965 and is headquartered in Berlin, Germany. | 9 años |
Timothy Richard Hughes | M | - | 2 años | |
Ram Sasisekharan | M | 58 |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | 9 años |
Michael Taylor | M | 69 | 7 años | |
Amos Ron | M | 68 | - | |
Edward Penhoet | M | 83 | 11 años | |
David Baltimore | M | 86 | 22 años | |
Robert Weiskopf | M | 73 | 12 años | |
Tiffany Crowell | F | - |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | - |
Shmuel Ben Zvi | M | 64 | 5 años | |
Dawn Schottlandt | F | - | 3 años | |
Adrian Senderowicz | M | 60 |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | 2 años |
Lisa Walters-Hoffert | F | 65 | 9 años | |
Nicole P. Jones | F | - |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | 1 años |
Charles Walker | M | 53 | 3 años | |
Marc Schegerin | M | 48 | 2 años | |
Michael P. Dillon | M | 57 | 5 años | |
Thomas Liquard | M | 51 | 1 años | |
Michael Ross | M | 75 | 4 años | |
Philip Serlin | M | 63 | - | |
Nerolie Phyllis Withnall | F | 80 | 10 años | |
Mel Bridges | M | 73 | 10 años | |
Steve Hall | M | 69 |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | 6 años |
Karen L. Roberts | F | 67 |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | 5 años |
Peter Svennilson | M | 62 | 5 años | |
Ronald Cohen | M | 68 | 7 años | |
William Ringo | M | 78 | 5 años | |
David Hastings | M | 62 | 5 años | |
David Walt | M | 71 |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | 2 años |
Lewis Coleman | M | 82 | 4 años | |
Robert Tepper | M | 68 |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | 9 años |
Franklin Berger | M | 74 | 5 años | |
Matthew Maurer | M | - | 2 años | |
Jennifer Pilcher | F | - | - | |
Imran Ahamed | M | - | 1 años |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Estados Unidos | 86 | 86.00% |
Australia | 8 | 8.00% |
Israel | 5 | 5.00% |
Alemania | 1 | 1.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Susan Kelley
- Red Personal